Porsche AG Books Lower Revenue, Profitability on Higher Costs
By David Sachs and Christian Moess Laursen
Porsche AG's revenue and profitability fell in the first quarter on higher costs from the ramp-up of new models.
The German luxury sports-car maker's quarterly revenue fell to 9.01 billion euros ($9.67 billion) from EUR10.10 billion a year prior. The figure missed analyst expectations of EUR9.33 billion, according to Visible Alpha.
Operating return on sales, a profitability measure, was 14.2%, down from 18.2% a year ago and below the company's reiterated full-year guidance of 15% to 17%.
Operating profit slipped to EUR1.28 billion, from EUR1.84 billion in the first quarter of last year.
The planned renewal of its model range caused increased research-and-development costs and marketing activities during the quarter, the company said.
"In the first quarter, we gained a lot of momentum to lay the groundwork for future success," Deputy Chairman Lutz Meschke said.
Besides backing its profitability target, Porsche kept its full-year guidance of revenue between EUR40 billion and EUR42 billion.
It delivered 3.9% fewer vehicles during the quarter, at 77,640.
Write to David Sachs at david.sachs@wsj.com
(END) Dow Jones Newswires
April 26, 2024 11:44 ET (15:44 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks